相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
Linda S. Steelman et al.
Oncotarget (2015)
A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung Cancer
Peter M. Ellis et al.
CLINICAL LUNG CANCER (2013)
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study
Julie M. Vose et al.
LEUKEMIA & LYMPHOMA (2013)
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
K. Mross et al.
BRITISH JOURNAL OF CANCER (2012)
Putting the brakes on p53-driven apoptosis
Katja Hoepker et al.
CELL CYCLE (2012)
p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors
Mourad Sanhaji et al.
CELL CYCLE (2012)
p53 reactivation The link to zinc
Gabriella D'Orazi et al.
CELL CYCLE (2012)
Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB
Carolina Vicente-Duenas et al.
CELL CYCLE (2012)
p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability
Cheng-Ming Chiang
CELL CYCLE (2012)
DEC1 and MIC-1 New players of p53-dependent cell fate decision
Yingjuan Qian et al.
CELL CYCLE (2012)
Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
A. Frost et al.
CURRENT ONCOLOGY (2012)
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2012)
Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo
Juping Yuan et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Three independent mechanisms for arrest in G2 after ionizing radiation
Kirsti Solberg Landsverk et al.
CELL CYCLE (2011)
Chromosome Segregation Errors as a Cause of DNA Damage and Structural Chromosome Aberrations
Aniek Janssen et al.
SCIENCE (2011)
Biological impact of freezing Plk1 in its inactive conformation in cancer cells
Sarah Keppner et al.
CELL CYCLE (2010)
p53-dependent repression of polo-like kinase-1 (PLK1)
Lynsey McKenzie et al.
CELL CYCLE (2010)
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2010)
Functional and Spatial Regulation of Mitotic Centromere-Associated Kinesin by Cyclin-Dependent Kinase 1
Mourad Sanhaji et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Yan Degenhardt et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells
N. N. Kreis et al.
ONCOGENE (2010)
The Plk1 Inhibitor BI 2536 Temporarily Arrests Primary Cardiac Fibroblasts in Mitosis and Generates Aneuploidy In Vitro
Bo Lu et al.
PLOS ONE (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1/CIP1
Nina-Naomi Kreis et al.
CELL CYCLE (2009)
A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
Wolfgang Reindl et al.
CHEMBIOCHEM (2009)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition
Nobumoto Watanabe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Plk1-mediated Phosphorylation of Topors Regulates p53 Stability
Xiaoming Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Polo-like kinases: conservation and divergence in their functions and regulation
Vincent Archambault et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
Patrick Schoffski
ONCOLOGIST (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
Inhibition of polo-like kinase 1 by blocking Polo-box domain-dependent protein-protein interactions
Wolfgang Reindl et al.
CHEMISTRY & BIOLOGY (2008)
Polo and Aurora kinases - lessons derived from chemical biology
Stephen Taylor et al.
CURRENT OPINION IN CELL BIOLOGY (2008)
Polo on the rise -: from mitotic entry to cytokinesis with Plk1
Mark Petronczki et al.
DEVELOPMENTAL CELL (2008)
Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
Klaus Mross et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of the novel Plk1 inhibitor ZK-Thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis
Anna Santamaria et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Mitotic drug targets and the development of novel anti-mitotic anticancer drugs
Mathias Schmidt et al.
DRUG RESISTANCE UPDATES (2007)
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1
Peter Lenart et al.
CURRENT BIOLOGY (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Timothy J. Lansing et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Opinion - Targeting polo-like kinase 1 for cancer therapy
K Strebhardt et al.
NATURE REVIEWS CANCER (2006)
Normal cells, but not cancer cells, survive severe Plk1 depletion
XQ Liu et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death
BAA Weaver et al.
CANCER CELL (2005)
Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals
R Guan et al.
CANCER RESEARCH (2005)
Polo-like kinases and oncogenesis
F Eckerdt et al.
ONCOGENE (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy
C Vogel et al.
ONCOGENE (2004)
Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation
K Ando et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
